Source comparison
How Long TB-500 Stays in System: Detection Method Comparison
Different assay methods detect TB-500 across different timeframes, and understanding these distinctions matters for research compliance and experimental design. Plasma ELISA Blood 24–48 hours 10–50 ng/mL Short-term pharmacokinetic studies; confirms recent admi
This comparison does not assign a generated winner or score.
- Different assay methods detect TB-500 across different timeframes, and understanding these distinctions matters for research compliance and experimental design.
- Plasma ELISA
- Blood
- 24–48 hours
- 10–50 ng/mL
- Short-term pharmacokinetic studies; confirms recent administration
- Useful only for acute detection. Misses tissue retention entirely
- Urine LC-MS/MS
- Urine
- 21–30 days
- 0.5–2 ng/mL
- Anti-doping compliance; regulatory washout verification
- Gold standard for detection avoidance. Longest window, highest sensitivity
- Tissue Biopsy Assay
- Muscle/synovial fluid
- 10–14 days
- 5–20 ng/g tissue
- Research validating local bioavailability and depot effects
- Invasive but definitive for proving tissue-level persistence beyond plasma clearance
- Endogenous TB4 Ratio
- Blood or urine
- 14–21 days (indirect)
- Ratio >2:1 vs baseline
- Distinguishing exogenous administration from natural TB4 fluctuation
- Adds 7–10 days to clearance window by detecting metabolic disruption, not just the peptide itself
- Plasma assays clear quickly but don't reflect therapeutic persistence. Urine mass spectrometry extends detection by weeks and is the method anti-doping agencies rely on. Tissue biopsy confirms that TB-500 remains bioavailable locally long after blood levels are undetectable, validating the twice-weekly dosing model used in most research protocols.